IN THE NEWS
Alexis Howerton On Starting Up From New Science
Source: Life Science Leader
By Wayne Koberstein, Executive Editor, Life Science Leader magazine
It is not often I meet my interview subject in the elevator on the way to our meeting room. By the time we get to the right floor, Alexis Howerton, the founding CEO of Spruce Biosciences, has recognized me from a photo and introduced herself, and we have already started the conversation. Our meeting was set only a day or so before we both attended this industry event, and I come knowing next to nothing about Spruce or its lead drug candidate, SPR001, now in midstage development for treating congenital adrenal hyperplasia (CAH).
Rare Disease Report: Spruce Launches CAH Natural History Study
Yesterday, in observance of Rare Disease Day, Spruce Biosciences announced the launch of the CAH Natural History Study, an initiative to advance knowledge and awareness of congenital adrenal hyperplasia (CAH).
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
Moriarty brings 18 years of clinical industry experience to Spruce to advance SPR001, the company’s lead program for congenital adrenal hyperplasia (CAH), through Phase 2 clinical trials and expand into additional indications
Spruce Biosciences Launches Natural History Study for Congenital Adrenal Hyperplasia in Time for World Rare Disease Day
Study Aims to Support Patients, Improve Care and Accelerate Research for Rare Disorder by Putting Power in Patients’ Hands